RxDoctor Payments Data

Bobbie West, MD

Emergency Medical Services · Jackson, MSNPI 1346285491

Payments from drug & device makers

What this record shows

8 manufacturers reported payments, led by Welch Allyn at 52.4% of the total. Reporting peaked in 2021 at $384 and has fallen 59.8% since, to $154 in 2025.

$701in general payments, 2019–2025

Across 17 payments — averaging $41.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Welch Allyn$368
  • Novo Nordisk$177
  • AbbVie$38
  • GSK$35
  • Pfizer$34
  • Merck$23
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$33448%
  • Other$36852%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Welch Allyn2$368
Novo Nordisk6$177
AbbVie2$38
GSK2$35
Pfizer2$34
Merck1$23
Medtronic1$14
Inari Medical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$701 in reported general payments places this provider in the 85th percentile of 25 emergency medical services providers in Mississippi.

See all emergency medical services providers in Mississippi

Medicare billing

Part B allowed, 2024
$96,144
Medicare patients
307
Services billed
2,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$51,481
EliquisApixaban30$28,255
MounjaroTirzepatide20$22,381
JardianceEmpagliflozin13$8,358
XareltoRivaroxaban12$4,736
SynthroidLevothyroxine Sodium40$2,270
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$2,254
Albuterol Sulfate HfaAlbuterol Sulfate71$1,243
Diclofenac Sodium50$1,129
Levothyroxine Sodium92$919
Rosuvastatin Calcium105$848
Doxycycline Hyclate105$847
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide53$760
Pantoprazole Sodium60$731
Tamsulosin Hcl49$723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$177$51,48152 claims
PfizerEliquis$34$28,25530 claims
AbbVieSynthroid$38$2,27040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 25 emergency medical services providers in Mississippi.

Other emergency medical services in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →